Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?

In the last years, adalimumab biosimilars have represented a commonly used alternative to the originator agent in the treatment of moderate to severe hidradenitis suppurativa. As of today, studies investigating the switch from adalimumab originator to biosimilar, following pharmacoeconomic policies,...

Descripción completa

Detalles Bibliográficos
Autores principales: Roccuzzo, Gabriele, Rozzo, Giulia, Burzi, Lorenza, Repetto, Federica, Dapavo, Paolo, Ribero, Simone, Quaglino, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788000/
https://www.ncbi.nlm.nih.gov/pubmed/36062429
http://dx.doi.org/10.1111/dth.15803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788000/
https://www.ncbi.nlm.nih.gov/pubmed/36062429
http://dx.doi.org/10.1111/dth.15803

Ejemplares similares